Friday, February 3, 2017

Drugs in Clinical Pipeline: LY3041658 | Treatment of Skin Diseases | Monoclonal Antibody | Chemokine (CXC) Antagonist

LY3041658 is (expected to be a) monoclonal antibody that targets and specifically bind seven human ELR+ CXC chemokines. Such antibodies are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

Eli Lilly is developing LY3041658 for the treatment of skin diseases. It is under Phase 1 clinical trials.

1. Beidler, C. B.; et. al. Pan-ELR+ CXC Chemokine Antibodies. US20140271647A1
2. A Study of LY3041658 in Participants With Skin Diseases. NCT02896868

Note: No article/publication is available for LY3041658. This report is based on in-house searches done for the molecule. It will be updated regularly.
1 2 3